QuidelOrtho (QDEL) vs SI-BONE (SIBN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
SI-BONE (SIBN) has outperformed QuidelOrtho (QDEL) over the past year, gaining 24.0% versus a loss of 52.2%. Over five years, SIBN leads with a -17.5% price change compared with -89.5% for QDEL. QuidelOrtho is the larger company by market cap ($920.3 million vs $868.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | QDEL | SIBN |
|---|---|---|
| Share price | $13.42 | $19.37 |
| Market cap | $920.28M | $868.14M |
| 1-day change | +8.14% | +2.70% |
| YTD return | -53.01% | -4.36% |
| 1-year return | -52.17% | +24.00% |
| 5-year return | -89.54% | -17.46% |
| Forward P/E | 9.31 | — |
| EPS (TTM) | $-15.39 | $-0.34 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $35.58 | $21.89 |
| 52-week low | $9.92 | $11.48 |
| Distance from 52-week high | -62.28% | -11.51% |
| Analyst consensus | hold | strong_buy |
| Avg. price target upside | +9.31% | +30.20% |
| Average volume | 1.51M | 543.48K |
| Shares outstanding | 68.58M | 44.82M |
| Employees | 6,500 | 376 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SIBN has outperformed QDEL by 76.2 percentage points over the past year.
About QuidelOrtho
QDEL stock →QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 6,500 employees
About SI-BONE
SIBN stock →SI-BONE, Inc., a medical device company, develops procedural solutions for compromised bone, grounded in expertise in biomechanical design and anatomy-specific applications in the United States and internationally. It offers a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products.
Health Care · Medical/Dental Instruments · 376 employees
QDEL vs SIBN FAQ
Which is bigger, QuidelOrtho or SI-BONE?
QuidelOrtho (QDEL) is larger, with a market capitalization of $920.28M compared with $868.14M for SI-BONE (SIBN).
Which stock has performed better over the past year, QDEL or SIBN?
SIBN returned +24.00% over the past 12 months, compared with -52.17% for QDEL (price return, excluding dividends). Past performance does not predict future results.
Are QuidelOrtho and SI-BONE in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: In Vitro & In Vivo Diagnostic Substances for QuidelOrtho and Medical/Dental Instruments for SI-BONE.